報價延遲最少15分鐘:2025/01/11 17:54 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.98 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.45/-0.46
|
|
企業價值
74.43M
|
| 資產負債 |
|
每股賬面淨值
-0.46
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
8.23M
|
|
每股收益
0.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:54 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. |